readthroughSign in
Nov 16, 2026FinancingUpdated

Azora Therapeutics reports Q3 2026 results, reaffirms AT177 IND timeline for first half of 2027

The company said it remains on track to submit an IND and begin a Phase 1a trial for ulcerative colitis candidate AT177 in the first half of 2027.

Azora Therapeutics, formerly Adial Pharmaceuticals, reported financial results for the quarter ended September 30, 2026 and gave a business update on November 12, 2026. The company's name change from Adial Pharmaceuticals to Azora Therapeutics took effect on October 29, 2026, when its shares began trading on The Nasdaq Capital Market under the ticker "AZR."

During the quarter, Azora continued to advance AT177 through IND-enabling studies and expanded its scientific and operating team, developing the drug as an oral, colon-targeted aryl-hydrocarbon receptor agonist intended to restore mucosal immune balance at the site of disease while limiting systemic exposure.1 The company said IND-enabling studies continued, building on completed GLP toxicology studies and pre-IND feedback from the FDA.1 GMP manufacturing was also initiated to support clinical development of AT177.1 Azora reiterated plans for an IND submission and initiation of a Phase 1a single- and multiple-ascending-dose (SAD/MAD) trial in the first half of 2027, subject to regulatory clearance.1

The company also announced leadership and board changes, naming Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist1, and appointed three independent directors on November 3, 2026.1

On financing, Azora amended its securities purchase agreement and note exchange agreements in September 2026 to remove a provision that reduced investors' milestone warrant purchase rights, with up to approximately $32.4 million in gross proceeds possible if investors elect to purchase the milestone warrants.1

Turning to cash, the company held $22.0 million in cash and cash equivalents as of September 30, 2026, compared to $28.7 million as of June 30, 2026.1 Azora said its existing cash and cash equivalents are expected to fund the company's current operating plan, including completion of IND-enabling studies and the Phase 1a trial, and that this does not assume any proceeds from the issuance and sale of milestone warrants.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.